Experimental drug profiles
Independent profiles of experimental medical drugs. Each one combines live clinical trial records and FDA status with our sourced analysis of the evidence: what the drug does, what the trials have shown, and what could change its prospects.
CagriSema
Novo Nordisk · Peptide combination (once-weekly injection) · Metabolic
Submitted to the FDA in December 2025 for weight management; decision expected in late 2026 (company-reported)
33 registered trials (20 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
FDA-approvedDaraxonrasib (Rasonque)
Revolution Medicines · Small molecule (oral, once daily) · Oncology
FDA-approved August 26, 2026 for previously treated metastatic pancreatic cancer after roughly doubling survival in Phase 3
22 registered trials (5 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
FDA-approvedEnlicitide (Lipfendra)
Merck & Co. (MSD) · Oral PCSK9 inhibitor (once-daily tablet) · Cardiovascular
FDA-approved July 2026 as the first oral PCSK9 inhibitor; cardiovascular outcomes trial ongoing
34 registered trials (8 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Major setbackIvonescimab
Summit Therapeutics · Bispecific antibody · Oncology
FDA issued a Complete Response Letter on November 15, 2026: progression-free survival improved, but overall survival was not statistically significant
192 registered trials (18 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Not yet approvedLepodisiran
Eli Lilly and Company · Small interfering RNA (siRNA) · Cardiovascular
Phase 3 outcomes trial (ACCLAIM-Lp(a)) underway; a single dose lowered Lp(a) by about 94% in Phase 2
8 registered trials (2 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Not yet approvedMuvalaplin
Eli Lilly and Company · Small molecule (oral, once daily) · Cardiovascular
First oral Lp(a)-lowering drug in a Phase 3 outcomes trial (MOVE-Lp(a)), now recruiting
6 registered trials (1 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Approved outside the U.S.Obicetrapib (Ubeslo)
NewAmsterdam Pharma · Small molecule (oral, once daily) · Cardiovascular
Approved in the EU in 2026 for high cholesterol; no FDA approval; 9,541-patient outcomes trial ongoing
29 registered trials (7 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Not yet approvedOlpasiran
Amgen · Small interfering RNA (siRNA) · Cardiovascular
Phase 3 cardiovascular outcomes trial ongoing; Phase 2 showed near-complete Lp(a) lowering
10 registered trials (3 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
FDA-approvedOrforglipron (Foundayo)
Eli Lilly and Company · Small molecule (oral, once daily) · Metabolic
FDA-approved for chronic weight management (April 2026); type 2 diabetes submitted in the U.S.
53 registered trials (29 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Major setbackPelacarsen
Novartis · Antisense oligonucleotide · Cardiovascular
Phase 3 outcomes trial missed its primary endpoint despite a 78% Lp(a) reduction
18 registered trials (8 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Not yet approvedRetatrutide
Eli Lilly and Company · Peptide (once-weekly injection) · Metabolic and cardiovascular
Phase 3 obesity program complete; Lilly plans to file with the FDA in Q1 2027
34 registered trials (14 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Approved outside the U.S.Sacituzumab tirumotecan
Merck & Co. (MSD) · Antibody–drug conjugate (ADC) · Oncology
Approved in China since 2024; under FDA priority review for previously treated endometrial cancer, decision date June 15, 2027 (company-reported)
129 registered trials (28 Phase 3 or later) · Evidence reviewed through Nov 20, 2026
FDA-approvedVepdegestrant (Veppanu)
Arvinas · PROTAC protein degrader (oral, once daily) · Oncology
FDA-approved May 1, 2026 for ESR1-mutated breast cancer: the first approved PROTAC
24 registered trials (2 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Not yet approvedZanzalintinib
Exelixis · Small molecule (oral, once daily) · Oncology
FDA decision for metastatic colorectal cancer extended to March 3, 2027 after a major amendment (company-reported)
51 registered trials (8 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
Not yet approvedZerlasiran
Silence Therapeutics · Small interfering RNA (siRNA) · Cardiovascular
Phase 2 complete; described by Silence as Phase 3-ready; Silence agreed to be acquired by Merck KGaA
2 registered trials (0 Phase 3 or later) · Evidence reviewed through Nov 19, 2026
What the status badges mean
- FDA-approved
- Approved by the FDA for at least one use. Other uses may still be in clinical trials.
- Approved outside the U.S.
- Approved by a regulator outside the United States, such as the European Commission, but not by the FDA.
- Not yet approved
- Not approved for any use. The drug is still being tested in clinical trials.
- Major setback
- A pivotal trial missed its main goal, or the FDA declined to approve the drug. Development may continue, and any approvals elsewhere are noted on the profile.
FDA status is checked against the FDA’s openFDA database. Each profile explains the decisions behind its badge, with sources.
How these profiles are built
- Trial records are imported from ClinicalTrials.gov and re-checked on every update. Changes to status, dates, and endpoints are logged.
- FDA status comes from the FDA’s openFDA database, not from company statements.
- Analysis is written by Spectral Genomics Editorial. Every claim is sourced, and company-reported results are labeled.
- Approval odds are shown only as labeled historical benchmarks. Read the methodology.